London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Brand..
How do you know RM is at ATS? Thanks!
RM is at ATS. There is no reason to be on proactive when he is in a room full of the most important people in the industry.
Fluvoxamine rejected by FDA
The FDA, however, said Monday that it was uncertain that the six-hour cutoff the Brazil study used was “a clinically meaningful threshold.”
I seem to recall making this point the other day about Eiger and being accused / abused by a certain poster for daring to question the efficacy’s behind it.
Doc83
I have a feeling RM is leaving...Not looking like he was part of the team that went
to ATS as far as we know..BUT more telling NO comment from him on today's
RNS...I would have thought significant news would merit a statement of some sort from the CEO....?
We may get some insight on 25th.....!!!
Depends on ACTIV2 in my view. If that is also very positive then more likely. Only time will tell. I’d be surprised if Polygon didn’t push for an application unless they know something else is happening in the background
Wrong. Happy to go through this again and not chuck in the towel.
Apologies, I meant to end that with saying I’m sure a lot of pained LTH’s would probably be happy being bought out for a few hundred million rather than go through all this again!
Tommy - realistically, what do you think the odds are that we’ll even apply for an EUA, never mind it being approved?
It has to be less than likely. Which means more trials. I’m not convinced Synairgen as it is right now can or should take this forward. If no TO then we are back to the long game of more trials.
Interesting that Eiger with their 2000 Patient trial have still not applied for an EUA after their presentation but still not published results which may explain why
I doubt anyone would sell it for a few hundred million before today and after today definitely not
Veru and Eiger are the two most recently. Veru looks a bit dodgy, but the Eiger trial was absolutely huge, 2000 patients and using interferon as well. So the market is more crowded. I still believe in the nebulised formula as having huge potential. But someone has to do something at the AGM. Peer reviewed papers aren't going to save lives or make money. I absolutely believe big pharma would buy this company for a few hundred million- its pocket change, and there is also the potential with COPD and other respiratory infections.Lets hope that Polygon can increase pressure.
Sid
You made some good points re patent a while ago. Thanks for that. Regarding the following:
"...but there are a lot of other companies now coming out with statistically significant results."
You couldn't do me a favor - when you get the time - and name a few of them. I can put them on my watch list!
Thanks.
Yes, a licencing or takeover deal looks to be the best opportunity for SNG. A global pharma would have the resources to upscale SNG001 / bring it to a world wide market much much quicker than Synairgen could ever do on its own. Good luck, Brighty
I stand by my assertion that Synairgen cannot do this alone. T/O or JV is going to be necessary. If a large trial takes another year commercialisation will be difficult. Huge room for SP rise if done right, but there are a lot of other companies now coming out with statistically significant results.
"the market for covid isn't as big or strong '
Just the tens of thousands of people dying every week, meh.
Fundamentals were yesterday we had little significant data of drug efficacy
Today we have potential 70% improvement in a range of studies in a population of 375-400 patients.
That’s quite a change.
Questions around the route ahead may well be answered on the 25th
Further evidence of what we all knew- that the drug has efficacy against Covid. However, the market for covid is not a big or as strong as it was and no way Synairgen has the resources to engage in another timely trial.
This should encourage other companies to take a look at SNG for takeover, particularly with good Activ 2. If there isn't one, I still doubt the ability of Synairgen to commercialise this at all.....